Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MOLN)
NASDAQ:MOLN
MOLN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.32 - $12.70
Previous CloseN/A
Volume8.30K
Average Volume (3M)4.43K
Market Cap
$160.44M
Enterprise Value$66.22M
Total Cash (Recent Filing)CHF24.03M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 25, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding40,374,640
10 Day Avg. Volume3,199
30 Day Avg. Volume4,434
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)28.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.38Price Target Upside165.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Molecular Partners News
PremiumCompany Announcements
Molecular Partners AG: Strategic Advances and Financial Overview
PremiumCompany Announcements
Molecular Partners and Orano Med Expand Cancer Therapy Collaboration
PremiumCompany Announcements
Molecular Partners Advances Radio-DARPin Programs with Strong Funding---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentMOLN's lead RDT program MP0712 is set to enter first-in-human studies and provide initial clinical data, highlighting its progress in clinical development.
Financial PositionThe company ended 3Q24 with CHF 143.6M in cash and equivalents, providing a cash runway into 2027.
Strategic PartnershipsThe revised collaboration agreement with Orano Med strengthened the partnership, supporting Molecular Partners Ag's RDT program development.
Bears Say
Market CompetitionMOLN can access tumor-associated antigens more selectively and more rapidly than companies dependent on small molecules or antibodies.
Technology DifferentiationMOLN has made substantial progress in dialing out off-target kidney exposure to its radioligands, further differentiating the RadioDARPin platform from competitors.
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.32 and its highest was $12.70 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $160.44M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Aug 25, 2025 which is in 130 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Mar 06, 2025. The company reported -$0.346 earnings per share for the quarter, beating the consensus estimate of -$0.448 by $0.102.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate is -0.45.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.346 in its last earnings report, beating expectations of -$0.448. Following the earnings report the stock price went up 2.245%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
---
Molecular Partners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.38 (165.47% Upside)
$10.38 (165.47% Upside)
Blogger Sentiment
Bullish
MOLN Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.69%
12-Months-Change
Fundamentals
Return on Equity
-33.54%
Trailing 12-Months
Asset Growth
-25.77%
Trailing 12-Months
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
---
MOLN Company Deck
---
MOLN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Molecular Partners' programs, particularly in the radio DARPin franchise and the improved efficacy of the 533-DARPIn program. The expansion of the Orano Med collaboration and strong financial position further bolster the company's outlook. However, the discontinuation of the Novartis collaboration and initial challenges with the T Cell Engager program were noted as setbacks. Overall, the highlights significantly outweigh the lowlights.Read More>---
MOLN Stock 12 Month Forecast
Average Price Target
$10.38
▲(165.47% Upside)
Technical Analysis
Sangamo Biosciences
―
Annexon Biosciences
―
Innate Pharma
―
Design Therapeutics
―
Third Harmonic Bio, Inc.
―
Best Analysts Covering MOLN
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-27.75%
reiterated a buy rating 6 months ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -27.75% per trade.
---